New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD (2)

STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...

Related Keywords

Japan ,Boston ,Massachusetts ,United States ,United Kingdom ,Switzerland ,Stockholm ,Sweden ,Uppsala ,Uppsala Lan ,South Korea ,Israel ,Australia ,China ,Canada ,Great Britain ,Swedish ,Oskar Bosson ,Jiang Millington ,Eisai Co Ltd ,Alzheimer Network Trials Unit ,Washington University School Of Medicine ,Ministry Of Health ,National Institute On ,Alzheimer Clinical Trial Consortium ,Uppsala University ,Vp Communications ,Drug Administration ,Novel Subcutaneous Administration ,National Institutes Of Health ,Nasdaq Stockholm ,Late Breaking Symposium ,Early Alzheimer ,Long Term Outcomes ,Predictive Biomarkers ,Novel Subcutaneous ,Clinical Trials ,Biologics License Application ,Director Corporate Communication ,Social Mediae Mail ,Innovative Licensing ,Access Pathway ,Clinical Trial Consortium ,National Institute ,National Institutes ,Tau Nexgen ,Dominantly Inherited ,Washington University School ,Commercialization Agreement ,Nasdaq Stockholm Large Cap ,